The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. by Rovida, Elisabetta et al.
This article was downloaded by: [Universita Degli Studi di Firenze]
On: 13 January 2015, At: 08:12
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House,
37-41 Mortimer Street, London W1T 3JH, UK
Click for updates
Cell Cycle
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/kccy20
The metabolically-modulated stem cell niche: a
dynamic scenario regulating cancer cell phenotype and
resistance to therapy
Elisabetta Rovidaa, Silvia Peppicellia, Silvia Bonoa, Francesca Bianchinia, Ignazia Tusaa, Giulia
Chelonia, Ilaria Marzia, Maria Grazia Cipolleschia, Lido Calorinia & Persio Dello Sbarbaa
a Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”; Università degli
Studi di Firenze & Istituto Toscano Tumori; Firenze, Italy
Accepted author version posted online: 31 Oct 2014.Published online: 06 Nov 2014.
To cite this article: Elisabetta Rovida, Silvia Peppicelli, Silvia Bono, Francesca Bianchini, Ignazia Tusa, Giulia Cheloni,
Ilaria Marzi, Maria Grazia Cipolleschi, Lido Calorini & Persio Dello Sbarba (2014) The metabolically-modulated stem cell
niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy, Cell Cycle, 13:20, 3169-3175, DOI:
10.4161/15384101.2014.964107
To link to this article:  http://dx.doi.org/10.4161/15384101.2014.964107
PLEASE SCROLL DOWN FOR ARTICLE
Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in
the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or
warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions
of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select
articles posted to institutional or subject repositories or any other third-party website are without warranty
from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of
merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this
article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The
accuracy of the Content should not be relied upon and should be independently verified with primary sources
of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands,
costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in
connection with, in relation to or arising out of the use of the Content.
 
This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and
use can be found at http://www.tandfonline.com/page/terms-and-conditions
 
It is essential that you check the license status of any given Open and Open Select article to confirm
conditions of access and use.
The metabolically-modulated stem cell niche: a dynamic scenario
regulating cancer cell phenotype and resistance to therapy
Elisabetta Rovida, Silvia Peppicelli, Silvia Bono, Francesca Bianchini, Ignazia Tusa, Giulia Cheloni, Ilaria Marzi,
Maria Grazia Cipolleschi, Lido Calorini*, and Persio Dello Sbarba*
Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”; Universita degli Studi di Firenze & Istituto Toscano Tumori; Firenze, Italy
This Perspective addresses the interac-tions of cancer stem cells (CSC) with
environment which result in the modula-
tion of CSC metabolism, and thereby of
CSC phenotype and resistance to therapy.
We considered first as a model disease
chronic myeloid leukemia (CML), which is
triggered by a well-identified oncogenetic
protein (BCR/Abl) and brilliantly treated
with tyrosine kinase inhibitors (TKi). How-
ever, TKi are extremely effective in inducing
remission of disease, but unable, in most
cases, to prevent relapse. We demonstrated
that the interference with cell metabolism
(oxygen/glucose shortage) enriches cells
exhibiting the leukemia stem cell (LSC)
phenotype and, at the same time, suppresses
BCR/Abl protein expression. These LSC are
therefore refractory to the TKi Imatinib-
mesylate, pointing to cell metabolism as an
important factor controlling the onset of
TKi-resistant minimal residual disease
(MRD) of CML and the related relapse.
Studies of solid neoplasias brought another
player into the control of MRD, low tissue
pH, which often parallels cancer growth
and progression. Thus, a 3-party scenario
emerged for the regulation of CSC/LSC
maintenance, MRD induction and disease
relapse: the “hypoxic” versus the “ischemic”
vs. the “acidic” environment. As these envi-
ronments are unlikely constrained within
rigid borders, we named this model the
“metabolically-modulated stem cell niche.”
The “Hypoxic” Stem Cell Niche
and Stem Cell Maintenance and
Cycling in “Hypoxia”
In the early ‘90, our laboratory elabo-
rated on the stem cell niche (SCN) model
proposed by Ray Schoefield in 1978 to
define tissue sites dedicated to the mainte-
nance of stem cell potential.1 We
addressed the effects of a low environmen-
tal oxygen tension on the maintenance of
haematopoietic stem cells (HSC) in vitro.
Overall, hematopoiesis was found
markedly reduced in low oxygen (1% oxy-
gen in incubation atmosphere, approxi-
mately corresponding to 10 mM O2 and
7.6 mmHg) with respect to air. On the
contrary, HSC endowed with marrow
repopulation ability (MRA), but not less
immature progenitors, are better main-
tained in low oxygen, where they are
selected and enriched.2 On the basis of
these in vitro data, we proposed the exis-
tence in vivo of “hypoxic” HSC niches,
where low oxygen tension would help
HSC to proliferate as stem cells and main-
tain stem cell potential (self-renewal)
while preventing their commitment to
clonal expansion. This scenario implies
that low oxygen tension is a physiological
feature of SCN, i.e. that an environment
which is “hypoxic” for the bulk of haema-
topoietic cells is actually “normoxic” for
HSC.3 Therefore, the term low oxygen
will be used herein on to refer to the
“hypoxic” conditions suitable for HSC
maintenance, while the term hypoxic
SCN will be maintained to indicate the
tissue sites where this maintenance is
ensured. Later studies of ours demon-
strated that: (a) provided an appropriate
combination of stem cell-active cytokines
is added to cultures, HSC expansion can
occur in low oxygen;4 (b) in low oxygen,
HSC have the option between cycling and
quiescence, while the bulk of cell popula-
tion is growth-arrested;5 (c) in low oxygen
(but not in air) stem cell potential is
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markedly enhanced in cells which have
undergone one replication cycle and is
rapidly lost when cycling is sustained
beyond the first cycle, indicating that low
oxygen steers cycling of HSC toward self-
renewal immediately after their rescue
from quiescence and temporarily antago-
nizes clonal expansion.6 The existence of
physiologically “hypoxic” conditions in
bone marrow (BM), as well as of hypoxic
SCN in vivo, was later confirmed by
others (for a review see ref. 7).
Selection of Leukemia Stem
and Progenitor Cell Subsets
in Low Oxygen
On the basis of all above, we investi-
gated on the effects of low oxygen on dif-
ferent types of leukemia cell populations.
Incubation of murine erythroleukemia
(MEL) cells in low oxygen markedly
reduced cell bulk with respect to time
zero,8 in keeping with what observed for
normal hematopoiesis. The maintenance
of stem cell potential in the few MEL cells
capable to stand low oxygen was deter-
mined by the culture-repopulation ability
(CRA) assay, an in vitro method to deter-
mine MRA.5,9 The CRA assay is based on
cell transfer from primary cultures where
the experimental treatment is carried out
(i.e., incubation in low oxygen) to non-
selective, growth-permissive secondary
cultures (i.e. incubated in air). Cells sur-
viving incubation in low oxygen were
capable of repopulating secondary cultures
efficiently, although with a kinetics signifi-
cantly delayed with respect to that exhib-
ited by equal numbers of cells transferred
from control primary cultures incubated
in air. Nevertheless, once repopulation
started, its kinetics was identical to that
obtained with control cells and reached
identical peak values. Moreover, when 5-
fluorouracil (5FU) was added to primary
cultures following cell selection in low
oxygen, the repopulation of secondary cul-
tures by low oxygen/5FU-resistant cells
(around 1% of the number plated in pri-
mary cultures) was delayed further, but,
again, exhibited kinetics and peak values
identical to those obtained with low
oxygen-resistant/5FU-sensitive cells. These
results indicated that stem cell potential is
maintained integrally in MEL cells after
their selection in low oxygen or suppres-
sion of their cycling fraction, although
this potential is exploited with different
kinetics, once conditions permissive for
clonal expansion are established.8 It is
worth pointing out here that the quiescent
(and thereby 5FU-resistant) leukemia cell
subset is believed to contain the high-end
of leukemia stem cell (LSC) compartment,
in particular the LSC sustaining minimal
residual disease (MRD), which eventually
determines relapse of leukemia in patients
where therapy has been successful in
inducing remission.
Overall, the results summarized above
indicated that: (1) different leukemia cell
subsets, including quiescent LSC, can be
individually selected in primary cultures
incubated in low oxygen; (2) the outcome
of this selection can be verified by deter-
mining the repopulation kinetics of sec-
ondary growth-permissive cultures (drug-
free, incubated in air) of CRA assays,
being the more delayed this repopulation,
the higher the hierarchical level of selected
cells.9 As these experiments were carried
out using a stabilized cell line, it emerged
that an appropriate manipulation of cul-
ture environment can reveal a marked
phenotypical heterogeneity within a clonal
cell population. On this basis, leukemia
cell lines appeared suitable to investigate
on the behavior and response to drug
treatments of different LSC as well as leu-
kemia progenitor cell (LPC) subsets.
Low Oxygen and Selection of
Chronic Myeloid Leukemia Cells
Insensitive to Therapy
Incubation in low oxygen of chronic
myeloid leukemia (CML) cells of stabi-
lized lines or primary explants completely
suppresses BCR/Ablprotein, the fusion pro-
tein responsible for CML pathogenesis.
Cells selected in low oxygen, which are
independent of BCR/Abl signaling for
persistence in culture, remain however
genetically leukemic, as they re-express
BCR/Ablprotein if cultures are shifted to
incubation in air. When the stem cell
potential of CML cells selected in low
oxygen is measured by CRA assay, they
repopulate the secondary cultures
incubated in air according to a delayed,
LSC-type kinetics. These findings have a
tremendous impact on CML cell resis-
tance to imatinib-mesylate (IM;
Gleevec), the prototype of tyrosine
kinase inhibitors (TKi) used for CML
therapy. Indeed, the stem cell potential of
cells selected in low oxygen is completely
insensitive to treatment with IM, because
its molecular target is suppressed in LSC,
while full sensitivity to IM is rescued in
the LSC progeny where BCR/Ablprotein is
re-expressed during incubation in non-
selective secondary cultures.10-12
These results led to link IM-resistance
to reversible BCR/Ablprotein suppression
and this suppression, in turn, to the suit-
ability of LSC to home in the hypoxic
SCN we had found to ensure HSC main-
tenance. This was a previously unde-
scribed mechanism of insensitivity to
IM which is appropriately referred to as
refractoriness. Indeed, the term primary
resistance should be reserved to a geneti-
cally-determined (and therefore irrevers-
ible) insensitivity to IM already present in
CML cells before the treatment starts, and
the term secondary resistance to that
induced in a cell subset by later BCR/Abl
mutations in IM-treated patients. The
capacity of LSC to nest in HSC niches
was later demonstrated.13,14
That the environment-induced LSC
insensitivity to IM we described is not a
genetically-blocked event, but a phenotyp-
ical adaptation has the following impor-
tant consequences. (1) All LSC, and not
just an LSC subset (following subset-
restricted mutations), are potentially
insensitive to TKi targeting BCR/Abl,
being stem cells inherently adaptable to
low oxygen. (2) It is predictable that even
the next generations of BCR/Abl-active
TKi, despite their enhanced action on
CML cell bulk,15 will be ineffective in
suppressing low oxygen-adapted LSC. (3)
Phenotypical, rather than genetical
changes explain easily the clinical finding
that relapse of disease upon IM discontin-
uation (which releases pressure against the
BCR/Ablprotein-dependent clonal expan-
sion of LSC) is very often sustained by a
cell population expressing wild-type
BCR/Abl, i.e., occurs in patients who have
not developed secondary resistance to
IM and therefore respond well to the
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reintroduction of IM after relapse.16,17 (4)
Our data are perfectly in keeping with the
observation that TKi-insensitive LSC
express BCR/Abl, being this expression
usually determined by FISH or PCR
instead of measuring protein levels.18-20
(5) Our model provides a conceptually
simple way to get out of the controversy as
to whether TKi actually inhibit BCR/Abl
kinase in BCR/Abl-positive CML cells
responsible for MRD.21-23
Our model predicts that LSC of CML
adapted to low oxygen are independent,
and deprived, of the selective advantage
represented by BCR/Abl signaling, i.e., are
not oncogene-addicted.24 Such an advan-
tage is useful to maximize the expansion
of cell population when environmental
conditions are permissive, but not to
enhance the maintenance of LSC respon-
sible for MRD when clonal expansion is
restrained. Indeed, what is crucial for LSC
maintenance is not the availability of
oncogenic growth-promoting signals, but
the capacity of cycling in low oxygen, i.e.,
a property that HSC physiologically
exhibit and is functional to steer mitotic
activity toward self-renewal (see above). In
this respect, one can envision LSC adapted
to low oxygen as revertant to a normal
phenotype. That LSC of CML cycle in
low oxygen is indicated by their sensitivity
to 5FU (unpublished data).
An extremely important consequence
of LSC cycling under conditions where
LSC are refractory to TKi is that cycling
fosters neoplastic progression while disease
remains at a subclinical level. Indeed,
cycling is necessary for transmission of
mutations to progeny.25 This is what we
define dynamic maintenance of MRD, a
phenomenon which we believe it is much
better suited than LSC quiescence to
explain the combination of insensitivity
to TKi with liability to neoplastic
progression.9
Glucose Shortage and Treatment-
Insensitive CML Cells
We deepened the effects of low oxygen
on BCR/Ablprotein expression and LSC
selection in CML cell populations by vary-
ing, at time zero of incubation, cell density
and glucose concentration in culture.11
While some BCR/Abl-dependent growth
was possible in low oxygen under non-
limiting glucose concentrations, glucose
exhaustion from culture medium emerged
as the critical condition for the reduction
of total cell number with respect to time
zero, as well as for BCR/Ablprotein suppres-
sion and the consequent acquisition of cell
refractoriness to IM. Long-sustained oxy-
gen/glucose shortage has been shown to
occur in vivo within neoplastic masses,
even to induce cell death in the bulk of
tumor.26,27 Within normal BM, the hyp-
oxic SCN represent ideal sites to get close
to glucose exhaustion, due to the
enhanced glucose consumption rate in
low oxygen (the Pasteur effect). We there-
fore hypothesized that glucose is con-
stantly at extremely low concentrations
within the core of hypoxic SCN, which
we defined, perhaps inappropriately,
“ischemic” SCN.9 The latter would repre-
sent the site of BCR/Abl-independent
LSC self-renewal and of dynamic mainte-
nance of IM-resistant MRD (Fig. 1). On
the other hand, within the poorly oxygen-
ated areas surrounding the “ischemic”
SCN core, BCR/Ablprotein expression
would be maintained and LSC progeny
would undergo clonal expansion,
exhibiting a BCR/Abl-dependent competi-
tive advantage over normal hematopoiesis.
The consequent high rate of glucose con-
sumption in peripheral areas of SCN
would contribute to maintain glucose
shortage in the core and thereby the func-
tional compartmentalization of SCN.
The above scenario impacts on the
“alternative” models proposed for the
origin of Cancer Stem Cells (CSC):
the CSC in normal stem cell and the CSC
in progenitor cell models.28 We believe
both models fit CML biology, being
the former adequate to describe
BCR/Ablprotein-negative LSC capable of
BCR/Abl-independent self-renewal (like
normal HSC) and the latter BCR/Ablprotein-
positive LSC where self-renewal is sustained
by BCR/Abl signaling (Fig. 2). This view is
well in keeping with the chiaroscuro model
proposed for a reversible transition between
normal haematopoietic stem and progeni-
tor cell phenotypes.29 The CML cells with
a relatively low sensitivity to IM described
in some studies are likely to be a mixture
of BCR/Ablprotein-negative and -positive
LSC.18-23 These phenotypical differences
are obviously restricted to CML, but the
dual metabolically-regulated CSC model
we propose may apply equally well to solid
Figure 1. Homing of immature CML cell subsets within the “hypoxic” or the “ischemic” stem cell
niche. Oxygen (O2) and glucose (gluc) concentrations decrease from the external to the internal
niche areas. Glucose shortage in the area where oxygen is exhausted drives BCR/Ablprotein suppres-
sion. LSC: leukemia stem cell; IM: imatinib-mesylate; white bolt: IM effective; gray bolt / X: IM
ineffective.
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tumors, where an abnormal and insufficient
vasculature often determines a reduced oxy-
gen and nutrient supply.26,27
Is There a Role for an “Acidic”
Leukemia/Cancer Stem
Cell Niche?
Although supported by a number of
experimental data, the cancer SCN model
we described above disregards an aspect,
low pH, which is a common feature of
poorly oxygenated tissue areas. In these
areas, low pH is due to the high lactate
and HC concentrations generated via the
enhanced glycolysis which is necessary to
maintain energy levels.30 Actually, tumor
cells rely on glycolysis for energy produc-
tion even when there is enough oxygen to
support mitochondrial function; this phe-
nomenon is known as aerobic glycolysis or
Warburg effect. Activation of glycolysis is
a necessary requirement for rapidly
expanding cell populations, as glycolysis
produces energy quickly (although less
efficiently than respiration), but also pro-
vides building blocks necessary to the syn-
thesis of macromolecules. This means that
the expansion of cell population would be
compromised if glycolysis were inhibited
just because there is enough oxygen
around to drive cell respiration.31,32 Thus,
the acidification of tumor cell masses is
due not only to poor blood perfusion and/
or diffusion across cancer tissue, but also
(and often perhaps mainly) to an intrinsic
property of proliferating cancer cells.
Actually, we believe that acidification usu-
ally precedes the onset of “hypoxic” condi-
tions, as it depends on glucose availability
rather than oxygen shortage. The presence
of acidic, but oxygenated, regions has
been indeed demonstrated in tumor xeno-
grafts.33 Overall, in cancer cell masses, the
effects of low pH may be independent of
those of low oxygen.
Low extracellular pH (pHe) in a tumor
is associated with poor prognosis,34 resis-
tance to radio- and chemo-therapy35 and
increased mutation rate.36 Low pHe also
promotes the rate of P-glycoprotein-
dependent transport across plasma mem-
brane, leading to reduced retention, and
thereby cytotoxic efficacy, of chemothera-
peutic drugs (a feature believed typical of
CSC). Accordingly, the normalization of
extracellular acidity may increase the che-
mosensitivity of tumor cells.37 We
recently found that in melanoma cells low
pHe promotes epithelial/mesenchymal
transition (EMT), reduces proliferation
rate and increases resistance to pro-apo-
ptotic agents via the NF-kB pathway.38
Thus, one can hypothesize that in tumor
cells acidity favors the selection of the
stem cell phenotype, which is often associ-
ated to EMT. In glioma cells, indeed,
acidity, independently of oxygen shortage,
promotes self-renewal, via mechanisms
which involve HIF-2a but are overall still
unclear.39
The low pHe of tumors derives from
the fact that the increase of intracellular
lactate and HC concentrations due to sus-
tained glycolysis could be lethal for cancer
cells if not kept under control. Therefore,
an additional adaptive feature of cancer
cells is the overexpression and increased
activity of cell surface transporters which
raise intracellular pH (pHi) via the extru-
sion of lactate and HC and the consequent
lowering of pHe.40,41 High pHi contrib-
utes to maintain glycolysis-driven prolifer-
ation, while low pHi inhibits glycolysis
and activates oxidative metabolism.42-44 It
has been reported that a shift toward low
pHe is associated with reduced glucose
consumption and lactate production, pro-
moting oxidative metabolism.45 The pres-
sure pH exerts on cells is powerful, as it
has been shown that at low pHe oxidative
metabolism is induced even in the pres-
ence of high glucose concentrations,
which enforce instead glycolysis at normal
pHe (Crabtree effect).
Overall, the above information points
to a linkage between acidity and oxidative
metabolism independently of glucose
availability. When glucose is limited or its
consumption is reduced due to low pH,
an AMPK-dependent arrest of anabolic
pathways occurs and metabolism is redir-
ected to fatty acid oxidation and oxidative
phosphorylation. Consequently, most
available substrates are consumed to maxi-
mize energy production, rather than to
sustain anabolic pathways critical to cell
proliferation, in keeping with what hinted
to at the beginning of this chapter.46 Such
a metabolic asset seems to suit CSC very
well, which more frequently than other
cancer cells just require energy levels suffi-
cient to survive, rather than those neces-
sary for clonal expansion. Accordingly,
mitochondria are necessary for HSC to
preserve their stemness and in particular
to control the balance between
Figure 2. “Metabolic” modulation of LSC phenotypes in CML. Relationship of different models for
the generation of CSC from normal immature cells (see ref. 28) to the expression of BCR/Abl protein
in LSC subsets and to their preferential homing in different tissue environments. CSC: cancer stem
cell; LSC: leukemia stem cell; LPC: non-stem leukemia progenitor cell; stem: stem cell; prog.: progen-
itor cell; SCN: stem cell niche; IM sens.: sensitivity to Imatinib-mesylate; curved arrows: self-renewal;
single straight arrows: hierarchical top-down phenotype shift; double straight arrows: clonal expan-
sion (symmetric division). Leukemic phenotypes: the width of single arrows reflects the different
behavior which likely characterizes the different LSC subsets. Note that the phenotype correspon-
dence (correspond.) between LSC and HSC does not necessarily imply that the latter are hosted in
low-glucose tissue areas (the issue is not addressed in this paper).
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self-renewing cell division and symmetri-
cally committed cell division.47 Thus,
CSC would be characterized by oxidative
metabolism and reduced oxygen/glucose
consumption, and would be hosted in
areas at low pHe and glucose availability
(Fig. 3).
Lagadinou et al. reported that LSC-
enriched acute myeloid leukemia cell pop-
ulations over-expressing BCL-2 produce
oxygen radicals as by-products of low-level
oxidative phosphorylation, and that in
these cells BCL-2 inhibition reduces oxi-
dative metabolism and selectively eradi-
cates quiescent LSC.48 LSC were defined
indeed unable to utilize glycolysis when
mitochondrial respiration is inhibited,
indicating in turn that mitochondrial res-
piration is active in these cells and neces-
sary to drive energy production from
glycolysis. Therefore, as summarized in
Figure 3, a low oxidative state49 (com-
bined with a low glycolytic rate) is likely
to characterize LSC specifically among
cells capable to stand low pH generated by
cells at high glycolytic rate. On the other
hand, metformin, an oral anti-diabetic
drug, was shown to target primary T-ALL
cell populations enriched in LSC,50 which
also suggests that LSC require oxidative
metabolism.51
Going back to the metabolic compart-
mentalization within the SCN, one can
hypothesize that peripheral SCN areas are
primarily characterized by a high rate of
glucose consumption and glycolysis (by
the oncogene-addicted cell bulk) rather
than by the exhaustion of available oxygen
and the consequent secondary enhance-
ment of glycolysis via the Pasteur effect.
Thus, the complete coverage of energy
needs by glycolysis in peripheral SCN
areas would lead to spare oxygen and
make it available in the SCN core to LSC/
CSC relying on oxidative metabolism
(Fig. 3). In keeping with this hypothesis,
we found that melanoma cells grown for
24h at low pH (6.7–6.9) in air maintain
100% viability even after 48 h of transfer
to 1% oxygen but do not survive when
transferred to 0.3% oxygen (unpublished
data), according to the observation that at
least 0.5% oxygen is required to keep oxi-
dative metabolism going.52,53 On this
basis, the term acidic SCN is perhaps
more appropriate than “ischemic” SCN to
define the sites where the more immature
LSC/CSC subset is maintained.
Of relevance to the cohabitation of
“glycolytic” and “oxidative” subsets of
immature cancer cells within the different
SCN regions is the metabolic symbiosis
demonstrated by Sonveaux et al.54 In this
scenario, lactate produced by “glycolytic”
cells is taken up by “oxidative” cells, which
use lactate via the tricarboxylic acid cycle
as their main substrate for mithocondrial
activity. This is the so-called reverse War-
burg effect, which has been shown to char-
acterize the metabolic symbiosis between
breast or prostate cancer cells and cancer-
associated fibroblasts.55,56 Whether the
reverse Warburg effect applies to leukemia
cells within the SCN of BM remains to be
demonstrated. However, the consumption
of lactate and its processing via an oxida-
tive metabolic pathway provides a likely
explanation as to how LSC/CSC can man-
age to produce enough energy within the
SCN core following glucose exhaustion in
the periphery. In this light, acidity may be
crucial to define the SCN core conditions,
rather than per se, in that it characterizes
the environment where lactate is supplied.
The concept of metabolic symbiosis ren-
ders borders within the niche difficult to
define (compare Figure 3 to Figure 1).
This conclusion is in keeping with other
information challenging the model of
location-dependent stem cell regulation
within tissues. It is considered very possi-
ble indeed that LSC/CSC are capable to
bounce flexibly and reversibly between a
lactate-producing and a lactate-consuming
state,57 as suggested by a report that cancer
cells which are at low oxygen at onemoment
may be well oxygenated an hour later and
viceversa.58 Further support to the view that
cells with different metabolic profiles may
cohabitate in the same environment came
from recent work indicating that the
“hypoxic” phenotype of HSC is cell-specific
rather than location-dependent.59
Concluding Remarks
All above points to a functional
compartmentalization of different LSC/
CSC subsets which is based on their meta-
bolic asset, rather than to a location-
centered compartmentalization related to
the availability of oxygen or glucose per se
in discrete SCN zones. In this respect, it is
Figure 3. Oxidative metabolism survives within the “acidic” core of stem cell niches. Glucose (gluc)
is exhausted in peripheral niche areas due to the high rate of glycolysis, resulting in the production
of lactate (lact), which diffuses to, and lowers pH in, the niche core (where pH reaches the lowest
levels). Oxygen is spared in the “glycolytic” periphery and let free to diffuse to the core, where it
contributes to lactate metabolism and the relative production of energy. According to this hypothe-
sis, niche periphery would home oxygen-independent CSC and niche core glucose-independent/
lactate-dependent CSC.
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mandatory to note that our conclusions
derive from the combination of informa-
tion relative to leukemias and solid
tumors, which commands to cross-
confirm experimentally the data we
referred to. As far as CML is concerned,
we can be reasonably sure that the condi-
tions we established in vitro for BCR/Abl
protein suppression reflect those enabling
the maintenance of IM-resistant MRD in
vivo. However, experiments directed to
the metabolic characterization of this phe-
nomenon are still going on in our labora-
tory. With respect to other neoplastic
diseases, including leukemias and solid
tumors, for which the molecular oncogen-
esis is less well characterized, we believe
that the homing of an LSC/CSC subset
within the SCN core is invariably paral-
leled by the suppression of all endogenous
stimuli to extensive proliferation and
clonal expansion.
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